George W. Lloyd sold $5.2M of RPRX
EVP, Investments & CLO at Royalty Pharma plc. 135,426 shares at an average of $38.34, traded Nov 19, 2025, filed Nov 21, 2025.
Score components
- +15RoleOfficer
- +25Trade size$5.2M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001814899-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC10b5-1 | -47,798 | $38.28 | $1.8M | 10,712 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2023 G HoldCo LLC10b5-1 | -4,628 | $39.01 | $181k | 6,084 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2020 G, LLC10b5-1 | -47,401 | $38.28 | $1.8M | 4,599 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2020 G, LLC10b5-1 | -4,599 | $39.01 | $179k | 0 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2021 G, LLC10b5-1 | -25,530 | $38.28 | $977k | 2,470 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Sharesindirect: By GWL 2021 G, LLC10b5-1 | -2,470 | $39.01 | $96k | 0 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Shares10b5-1 | -2,770 | $38.29 | $106k | 230 | Nov 21, 2025 |
| Nov 19, 2025 | SOpen-market sale Class A Ordinary Shares10b5-1 | -230 | $39.03 | $8,978 | 0 | Nov 21, 2025 |
Related signals
Other insiders at Royalty Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $236k 4,126 shares | -100% | |
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $239k 4,126 shares | -50% | |
| 43Moderate | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $5.9M 100,000 shares | -27% | |
| 37Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $786k 20,000 shares | -17% | |
| 37Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $768k 20,000 shares | -14% | |
| 55Moderate | Royalty Pharma plc | George W. Lloyd EVP, Investments & CLO | $4.2M 110,000 shares | -100% | |
| 47Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $2.7M 69,582 shares | -12% | |
| 37Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $766k 20,000 shares | -13% | |
| 40Moderate | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $1.6M 41,576 shares | -23% | |
| 55Moderate | Royalty Pharma plc | George W. Lloyd EVP, Investments & CLO | $4.4M 110,000 shares | -50% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.